111 results about "Lung infection" patented technology

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The utility model provides an auxiliary abdomen pressing device which comprises an abdominal belt and pressing assemblies, hook-and-loop fasteners capable of being adhered to each other are fixedly arranged at the two ends of the abdominal belt, and at least one pressing assembly is fixedly arranged in the middle of the back face of the abdominal belt. The pressing assembly comprises a supporting seat, a motor, a rotating shaft and pressing pieces, the supporting seat is integrally U-shaped, the motor is fixedly installed on the side portion of the supporting seat, the rotating shaft is horizontally installed in the supporting seat, the motor can drive the rotating shaft to rotate, and at least one pressing piece is installed on the rotating shaft and extends out of an opening of the supporting seat; the auxiliary abdomen pressing device is fixed to the upper abdomen of a patient through the abdominal belt, when the patient coughs, the motor rotates to drive the pressing piece to rotate anticlockwise so that the abdomen can be pressed inwards and upwards, the pressing duration can be adjusted and controlled, the consistent abdomen pressing strength can be kept all the time, and the auxiliary abdomen pressing effect is better; the abdominal pressure is increased to enhance the cough strength of the patient, so that the patient is assisted to effectively cough, sputum excretion is promoted, and the pulmonary infection opportunity is reduced.

The invention is suitable for the technical field of model prediction, and provides a method and system for constructing a pulmonary infection risk prediction model based on machine learning, and the method comprises the following steps: collecting data information, and carrying out the standardization processing of the data information, the data information comprising structured data, image data, time series data and environment data; performing multi-modal feature extraction based on the data information to obtain an image feature F1, a physiological time sequence feature F2 and an environment feature F3; performing multi-modal feature fusion, determining weights of the image features, the physiological time sequence features and the environment features, and adaptively adjusting the weights of the environment features based on seasonal factors; processing class imbalance through focus loss, determining a time decay weight according to infection latency characteristics, and determining a total loss function; and carrying out model training by adopting a multi-layer perceptron to obtain a pulmonary infection risk prediction model. According to the invention, by introducing the seasonal factor and the seasonal sensitivity coefficient, adaptive adjustment of the environmental feature weight is realized.

The invention provides application of a traditional Chinese medicine composition in preparation of medicines for preventing and / or treating influenza A and related diseases thereof. The traditional Chinese medicine composition comprises the following components or is prepared from the following raw material medicines in parts by weight: 20-40 parts of gypsum, 10-30 parts of wild buckwheat rhizome, 10-30 parts of herba houttuyniae, 3-15 parts of roasted herba ephedrae, 3-15 parts of fried semen armeniacae amarae, 3-15 parts of bulbus fritillariae cirrhosae, 5-25 parts of herba ardisiae japonicae, 3-15 parts of folium eriobotryae, 3-15 parts of fried fructus perillae and 3-15 parts of roasted radix glycyrrhizae. The traditional Chinese medicine composition disclosed by the invention has a relatively good inhibition effect on influenza A viruses, is low in toxicity and high in safety, also has a good anti-influenza A virus infection effect, and can provide a basis for clinically treating pulmonary infection caused by the influenza A viruses.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

The invention discloses a thoracic surgery pulmonary infection effusion drainage device and belongs to the technical field of medical instruments, the thoracic surgery pulmonary infection effusion drainage device comprises a drainage catheter structure, a filtering structure and a connecting assembly, the drainage catheter structure comprises an insertion tube, the two ends of the insertion tube are connected with a fixing tube and a hemispherical end respectively, and a partition plate is arranged in the insertion tube and the fixing tube; a plurality of drainage holes are formed in the end, close to the hemispherical end, of the insertion tube in the circumferential direction, and a medicine feeding hole is formed in the portion, above the drainage holes, of the insertion tube and communicated with the monitoring cavity. By means of the semispherical end and the drainage hole of the drainage catheter structure, lung tissue is prevented from being scratched when thoracic wall puncture is conducted, the lung tissue damage rate can be reduced to be smaller than or equal to 0.5%, drainage, pressure monitoring and drug administration are achieved through the double-cavity structure, one-time puncture is completed, and the pain of a patient is relieved; by arranging the partition plate, the drainage cavity and the monitoring cavity are isolated, liquid medicine is prevented from polluting an effusion sample, and the infection risk is reduced.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention discloses a bacteriophage gel microsphere as well as a preparation method and application thereof. The preparation method is simple and easy to implement and convenient to operate and popularize. Meanwhile, the prepared bacteriophage gel microspheres are high in loading capacity and can effectively load bacteriophages, the high porosity and the porous structure can provide a large number of binding sites for the bacteriophages, the contact opportunity of the bacteriophages and bacteria is increased, and the antibacterial efficiency is improved. In addition, the hydrogel property of the bacteriophage gel microspheres can protect the bacteriophage from being influenced by adverse environmental factors such as dryness and high temperature, and the stability of the bacteriophage in practical application is improved. In addition, compared with bacteriophage hydrogel microspheres prepared in the prior art, the bacteriophage gel microspheres prepared in the invention have smaller particle size, so that multi-way administration modes such as treatment of pulmonary infection by atomization administration and the like can be carried out.

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention belongs to the technical field of nano diagnosis and treatment agents, and particularly relates to a preparation method and application of a multi-field response type nano diagnosis and treatment agent, the preparation method of the multi-field response type nano diagnosis and treatment agent comprises a core layer, a middle shell layer and an outer wrapping layer, the core layer is DCNPs, the middle shell layer is Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs, and the outer wrapping layer is an Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs. And the outer coating layer is HA which is coated on the outer side of the Nd < 0.03 > Fe < 0.97 > Se < 2 >. According to the invention, a multi-mode therapy of membrane structure defect induction-oxidative stress-metabolism interference-energy blocking can be realized, the mucous barrier penetrating ability is good, the retention ability of DNH in a pulmonary infection focus is improved, efficient drug delivery is realized, real-time NIR-II diagnosis can be assisted, and the application prospect is wide. The efficient treatment of lung bacterial infection diseases is realized.

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

The present invention provides an inhalable bionic nanomaterial for treating bacterial pneumonia of the lungs, and a preparation method and application thereof, belonging to the technical field of drug preparation. Mesoporous polydopamine nanoparticles A are prepared by a one-pot synthesis method using block polyether and 3,3',5,5'-tetramethylbenzidine as templates; levofloxacin is added to A, stirred and centrifuged, and freeze-dried to obtain nanoparticles B; RAW264.7 cells are resuspended after centrifugation, homogenized and centrifuged again to collect the supernatant, and the supernatant centrifugal precipitation is the prepared macrophage membrane C; the configured B solution and C are mixed, and a bionic nanomaterial D wrapped in a macrophage membrane coating is prepared by a direct extrusion method. The inhalable bionic nanomaterial prepared by the present invention can cross the complex lung barrier to target the inflammatory site to respond to the release of drugs, and can remove reactive oxygen to relieve lung inflammation, which is of great significance for the treatment of lung infection and has promotion and application value.

Compositions, kits, and systems are disclosed that contain at least one senolytic agent. The compositions, kits, and systems may be utilized, for example, in a method of treating at least one lung infection in a patient. In a particular (but non-limiting) embodiment, the compositions, kits, and systems may be utilized in a method of treating at least one infection in a cystic fibrosis patient.

The invention discloses a compound traditional Chinese medicine composition for adjuvant therapy of cerebral hemorrhage combined with pulmonary infection. The compound traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-60 parts of ephedra, 90-120 parts of gypsum, 30-50 parts of almond, 150-180 parts of raw astragalus membranaceus, 100-120 parts of radix stephaniae tetrandrae, 90-120 parts of ginseng, 60-80 parts of radix bupleuri, 40-60 parts of fructus aurantii, 20-40 parts of platycodon grandiflorum, 150-180 parts of honey-fried licorice root, 45-80 parts of mint and 3-4 parts of borneol. The compound traditional Chinese medicine composition disclosed by the invention can be prepared into a dosage form of spray, and compared with traditional decoction for oral administration, the compound traditional Chinese medicine composition is convenient to use and less in liquid intake, and meanwhile, gastrointestinal reaction and vomiting are avoided, and the risk of secondary aspiration is reduced.

Blood and lung infection is a worldwide health problem, and about five millions of cases of death each year. Early treatments can help rescue life but require better tests to identify these infections. The invention recognizes pathogens, in particular those having antibiotic resistance, more quickly. The invention allows appropriate antibiotic treatment to be performed at an earlier point in time. Data from deep RNA sequencing of human blood is used to create a faster diagnostic test against infection and related antimicrobial resistance.

The invention belongs to the technical field of health-care products, and particularly relates to a probiotic composition for improving health of an oral cavity and an upper respiratory tract and a preparation method of the probiotic composition. Oral health is an important component of whole body health. Bacterial infections in the oral cavity, such as caries and periodontal diseases, not only influence the oral cavity, but also possibly harm the whole body health and influence the quality of life. The oral cavity is a portal of the respiratory tract, and bad oral hygiene may cause the accumulation of tartar, plaque, soft dirt and the like in the oral cavity and becomes a repository of pathogenic bacteria of the respiratory tract. When the immunity is low, the bacteria may enter the lung through the respiratory tract to cause respiratory tract and even lung infection. The invention discloses a probiotic composition for improving health of oral cavity and upper respiratory tract, which has the effects of resisting inflammation, resisting infection, preventing decayed teeth, protecting oral mucosa, preventing and treating bad breath and the like through the synergistic effect of streptococcus salivarius subsp. Thermophilus K12, lactobacillus rhamnosus CRL1505, lactobacillus salivarius NHNK612, lactobacillus mucus NHNK606 and the like.

The present disclosure relates to a lung infection area segmentation method and device, an electronic device and a storage medium. The method comprises: performing feature extraction processing on a lung image to obtain a plurality of high-level features; performing multi-scale fusion processing on the high-level features to obtain high-level enhanced features; performing global information extraction on the high-level enhanced features to obtain global guidance features; and performing multi-layer feature interaction processing on the high-level features by using the global guidance features to obtain lung features, wherein the lung features are used to represent a lung infection area of the lung image. The embodiments of the present disclosure can improve the lung infection area segmentation accuracy.

Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed. Kits including tafenoquine and means for testing for a viral infection are disclosed.

The invention discloses a polyclonal antibody for treating pulmonary infection as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: culturing pathogenic bacteria causing pulmonary infection by taking pig lung tissues as a culture medium, collecting the tissues, and homogenizing to obtain homogenate; performing antigen extraction and purification treatment on the homogenate, and performing inactivation treatment to obtain an inactivated antigen; immunizing a horse with the inactivated antigen, and collecting and separating to obtain serum; and carrying out antibody extraction and purification on the serum to obtain the polyclonal antibody. The prepared polyclonal antibody has the advantages of strong neutralization broad spectrum, high neutralization activity and good pulmonary infection treatment effect.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

The invention discloses a compound polymyxin inhalation preparation which is composed of polymyxin polypeptides, aminoglycoside antibiotics and pharmaceutically acceptable auxiliary materials, the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the inhalation preparation is (1: 20)-(1: 80), and the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the compound proportion is 1t compared with the molar ratio of a single component or the molar ratio of the aminoglycoside antibiotics in the single component; a compound proportion condition of 1: 20 can significantly reduce lung toxicity and also can achieve a drug effect of significantly eliminating lung infection multi-drug-resistant bacteria, the compound drug is delivered by adopting an inhalation liquid preparation form, the total drug delivery efficiency of aerosol inhalation is greatly improved, the median particle size of the drug is smaller, the proportion of particles smaller than 5 [mu] m exceeds 55%, and the drug delivery efficiency of aerosol inhalation is greatly improved. The medicine is more easily inhaled into the lung to achieve an anti-infection treatment effect.

Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

The present specification provides methods and compositions for treating fibrosis, in particular pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or occur after a pulmonary infection. The pulmonary infection may be caused by SARS-CoV-2. Lung function is stabilized or improved due to treatment.

The present invention relates to the field of medical instruments, and in particular to a subglottic drainage and flushing device suitable for outdoor environments, comprising an endotracheal tube, a balloon pressure measuring assembly being installed on the surface of the endotracheal tube, a balloon being provided on the surface of the endotracheal tube, a drainage tube being fixedly connected to the surface of the endotracheal tube, one end of the drainage tube being movably connected to a medical three-way tube, one end of the medical three-way tube being movably connected to a third connecting tube, a negative pressure suction assembly being movably installed on the other end of the medical three-way tube, a heating assembly being detachably connected to the surface of the third connecting tube, and one end of the third connecting tube being movably connected to a physiological saline bag. The flushing device can be controlled by a motor so that the pressure of the physiological saline is controllable during flushing, thereby preventing excessive pressure from forming a gap between the balloon and the airway wall or even causing damage to the balloon, leading to lung infection in the patient, and thereby facilitating the subglottic flushing operation of medical personnel.